Patents by Inventor Christopher A. Maack

Christopher A. Maack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5723441
    Abstract: Treatment with IGF/IGFBP-3 complex increases renal tubular mass and potentiates and/or stimulates kidney function in subjects suffering from acute and chronic renal failure or insufficiency resulting from such disorders as glomerulonephritis, glomerulosclerosis, interstitial nephritis, acute tubular necrosis due to ischemia and drug-induced toxicity, diabetic and autoimmune nephropathies and renal dysfunction due to acute and chronic rejection episodes in post-transplantation patients.
    Type: Grant
    Filed: August 31, 1995
    Date of Patent: March 3, 1998
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Howard R. Higley, Christopher A. Maack
  • Patent number: 5643867
    Abstract: This is a method for treating catabolic conditions in individuals by administering a composition containing a complex of insulin-like growth factor (IGF) and insulin-like growth factor binding protein-3 (IGFBP-3).
    Type: Grant
    Filed: March 29, 1995
    Date of Patent: July 1, 1997
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Christopher A. Maack, Andreas Sommer
  • Patent number: 5527776
    Abstract: This invention includes a method of treating subjects with immunologic and hematologic disorders, such as immune deficiencies and anemias characterized by deficient total hemoglobin. The treatment includes administering to the subject insulin-like growth factor binding protein-3 (IGFBP-3), alone or in a complex including an insulin-like growth factor (IGF), in an amount sufficient to improve the immunologic and/or hematologic disorder, for example, increasing the level of total hemoglobin or improving immune deficiencies, such as occur post-chemotherapy. Another aspect of the invention includes administering IGFBP-3 alone to treat IGF-driven lymphoproliferative conditions, such as leukemias, inflammatory skin diseases, and nasal polyps.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: June 18, 1996
    Assignee: Celtrix Pharmaceuticals
    Inventors: Joseph A. Carlino, Howard R. Higley, Christopher A. Maack
  • Patent number: 5407913
    Abstract: This is a method for enhancing systemic tissue repair in patients with burns, trauma and peptic ulcers, as well as patients about to undergo, is undergoing or just having undergone surgery. The method comprises systemically administering to such individuals a therapeutic composition comprising IGF and IGFBP. The preferred form is IGF-I/IGFBP-3.
    Type: Grant
    Filed: December 3, 1992
    Date of Patent: April 18, 1995
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Christopher A. Maack